EPISODE · May 2, 2022 · 15 MIN
Precision Medicine in Oncology: Ep.11. Selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer
from IMPACT Medicom · host IMPACT Medicom
Welcome to episode 11 of our Precision Medicine in Oncology series. In this episode, we discuss the development of a pan-Canadian consensus paper on the selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer.Our Guest:Our guest for this episode is Dr. Anna Tinker, Medical Oncologist at BC Cancer in Vancouver, Canada. Dr. Tinker is also a Clinical Associate Professor in the Department of Medicine at the University of British Columbia.This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Embed this episode
What this episode covers
Welcome to episode 11 of our Precision Medicine in Oncology series. In this episode, we discuss the development of a pan-Canadian consensus paper on the selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer. Our Guest: Our guest for this episode is Dr. Anna Tinker, Medical Oncologist at BC Cancer in Vancouver, Canada. Dr. Tinker is also a Clinical Associate Professor in the Department of Medicine at the University of British Columbia. This podcast episo...
Ready to play
Precision Medicine in Oncology: Ep.11. Selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.